| Applications: |
CLIA |
| Reactivity: |
Human |
| Note: |
FOR SCIENTIFIC EDUCATIONAL RESEARCH USE ONLY (RUO). MUST NOT BE USED IN DIAGNOSTIC OR OTHER MEDICAL APPLICATIONS. |
| Sensitivity: |
18.75pg/mL |
| Detection Limit: |
31.25~2000pg/mL |
| Short Description: |
This human DMD kit is a highly sensitive in-vitro chemiluminescent immunoassay for the measurement of trace amounts of analytes. |
| Storage Instruction: |
If unopened the kit may be stored at 2-8°C for up to 1 month. If the kit will not be used within 1 month, store the components separately, according to the component table in the manual. |
| Assay Time: |
3.5h |
| Detection: |
Chemiluminescence |
| Gene Symbol: |
DMD |
| Gene ID: |
1756 |
| Uniprot ID: |
DMD_HUMAN |
| Specificity: |
This kit recognizes Human DMD in samples. No significant cross-reactivity or interference between Human DMD and analogues was observed. |
| Sample Type: |
Serum, plasma and other biological fluids |
| Tissue Specificity | Expressed in muscle fibers accumulating in the costameres of myoplasm at the sarcolemma. Expressed in brain, muscle, kidney, lung and testis. Most tissues contain transcripts of multiple isoforms. Isoform 15: Only isoform to be detected in heart and liver and is also expressed in brain, testis and hepatoma cells. |
| Function | Anchors the extracellular matrix to the cytoskeleton via F-actin. Ligand for dystroglycan. Component of the dystrophin-associated glycoprotein complex which accumulates at the neuromuscular junction (NMJ) and at a variety of synapses in the peripheral and central nervous systems and has a structural function in stabilizing the sarcolemma. Also implicated in signaling events and synaptic transmission. |
| Protein Name | Dystrophin |
| Database Links | Reactome: R-HSA-3000171Reactome: R-HSA-390522 |
| Cellular Localisation | Cell MembraneSarcolemmaPeripheral Membrane ProteinCytoplasmic SideCytoplasmCytoskeletonPostsynaptic Cell MembraneIn Muscle CellsSarcolemma Localization Requires The Presence Of Ank2While Localization To Costameres Requires The Presence Of Ank3Localizes To Neuromuscular Junctions (Nmjs)In Adult MuscleNmj Localization Depends Upon Ank2 PresenceBut Not In Newborn Animals |
| Alternative CLIA Names | Dystrophin CLIA kitDMD CLIA kit |
| Specificity | This kit recognizes Human DMD in samples. No significant cross-reactivity or interference between Human DMD and analogues was observed. |
| Reproducibility | Both intra-CV and inter-CV are |
Information sourced from Uniprot.org
| Item | Specifications | Storage |
| Micro CLIA Plate (Dismountable) | 96T: 8 wells ×12 strips strips | -20℃, 6 months |
| Reference Standard | 96T: 2 vials 48T: 1 vial | -20℃, 6 months |
| Concentrated Biotinylated Detection Ab (100×) | 96T: 1 vial, 120 μL 60 μL | -20℃, 6 months |
| Concentrated HRP Conjugate (100×) | 96T: 1 vial, 120 μL 60 μL | -20℃ (Protect from light), 6 months |
| Reference Standard & Sample Diluent | 1 vial, 20 mL | 2-8°C, 6 months |
| Biotinylated Detection Ab Diluent | 1 vial, 14 mL | 2-8°C, 6 months |
| HRP Conjugate Diluent | 1 vial, 14 mL | 2-8°C, 6 months |
| Concentrated Wash Buffer (25×) | 1 vial, 30 mL | 2-8°C, 6 months |
| Substrate Reagent A | 1 vial, 5 mL | 2-8℃ (Protect from light) |
| Substrate Reagent B | 1 vial, 5 mL | 2-8℃ (Protect from light) |
| Plate Sealer | 5 pieces | |
| Manual | 1 copy | |
| Certificate of Analysis | 1 copy | |
| Sample Type | Range (%) | Average Recovery (%) |
| Serum(n=8) | 97-113 | 105 |
| EDTA plasma(n=8) | 100-114 | 108 |
| Cell culture media(n=8) | 90-106 | 96 |
| | Intra-assay Precision | Intra-assay Precision | Intra-assay Precision | Inter-assay Precision | Inter-assay Precision | Inter-assay Precision |
| Sample | 1.00 | 2.00 | 3.00 | 1.00 | 2.00 | 3.00 |
| n | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 |
| Mean (pg/mL) | 104.54 | 224.07 | 923.09 | 105.32 | 227.03 | 876.23 |
| Standard deviation | 11.04 | 23.17 | 92.03 | 9.26 | 21.61 | 95.42 |
| CV (%) | 10.56 | 10.34 | 9.97 | 8.79 | 9.52 | 10.89 |
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
